跳至主要内容
临床试验/IRCT2016110730621N1
IRCT2016110730621N1已完成3 期

Evaluation of efficacy of topical formulation of silymarin in prevention and management of hand-foot syndrome induced by capecitabine in patients with gastrointestinal malignancies

Mashhad University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • inclusion criteria: age between 18-70 years- gastrointestinal tract malignancies who treated with chemotherapy regimen included capecitabine
  • exclusion criteria: hepatic failure (LFT >5times of upper limit normal, or >3time of upper limit normal and symptoms), renal failure (GFR<30), severe infection requiring antibiotic therapy, dissatisfaction of patient, history of allergy to silymarin, autoimmune disease history, diabetes mellitus, concomitant use of NSAIDs, corticosteroids, other immunosuppressive drugs

排除标准

  • 未提供

研究者

相似试验